by Marisa Wexler, MS | Dec 19, 2025 | Myeloma News
Immuneering is preparing to launch a Phase 3 clinical trial to test its experimental therapy, atebimetinib, in people with pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer. The company recently received positive feedback from the U.S....
by MM360 Staff | Dec 19, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Marisa Wexler, MS | Dec 18, 2025 | Myeloma News
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The clinical trial (NCT06910306), sponsored by Alpha DaRT’s developer, Alpha Tau Medical, is expected to enroll...
by MM360 Staff | Dec 18, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Marisa Wexler, MS | Dec 17, 2025 | Myeloma News
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start in the first quarter of 2026. The trial is being conducted by Ideaya Biosciences, which is developing IDE034...
by MM360 Staff | Dec 17, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
